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Connecting gene expression data from
connectivity map and in silico target predictions
for small molecule mechanism-of-action analysis†
Aakash Chavan Ravindranath,‡a Nolen Perualila-Tan,‡b Adetayo Kasim,c
Georgios Drakakis,a Sonia Liggi,a Suzanne C. Brewerton,d Daniel Mason,a
Michael J. Bodkin,d David A. Evans,d Aditya Bhagwat,e Willem Talloen,f
Hinrich W. H. Go¨hlmann,f QSTAR Consortium,§ Ziv Shkedy*b and Andreas Bender*a
Integrating gene expression profiles with certain proteins can improve our understanding of the fundamental
mechanisms in protein–ligand binding. This paper spotlights the integration of gene expression data and target
prediction scores, providing insight into mechanism of action (MoA). Compounds are clustered based upon
the similarity of their predicted protein targets and each cluster is linked to gene sets using Linear Models for
Microarray Data. MLP analysis is used to generate gene sets based upon their biological processes and a
qualitative search is performed on the homogeneous target-based compound clusters to identify pathways.
Genes and proteins were linked through pathways for 6 of the 8 MCF7 and 6 of the 11 PC3 clusters. Three
compound clusters are studied; (i) the target-driven cluster involving HSP90 inhibitors, geldanamycin and
tanespimycin induces differential expression for HSP90-related genes and overlap with pathway response to
unfolded protein. Gene expression results are in agreement with target prediction and pathway annotations
add information to enable understanding of MoA. (ii) The antipsychotic cluster shows differential expression for
genes LDLR and INSIG-1 and is predicted to target CYP2D6. Pathway steroid metabolic process links the
protein and respective genes, hypothesizing the MoA for antipsychotics. A sub-cluster (verepamil and
dexverepamil), although sharing similar protein targets with the antipsychotic drug cluster, has a lower
intensity of expression profile on related genes, indicating that this method distinguishes close sub-clusters
and suggests differences in their MoA. Lastly, (iii) the thiazolidinediones drug cluster predicted peroxisome
proliferator activated receptor (PPAR) PPAR-alpha, PPAR-gamma, acyl CoA desaturase and significant
differential expression of genes ANGPTL4, FABP4 and PRKCD. The targets and genes are linked via PPAR
signalling pathway and induction of apoptosis, generating a hypothesis for the MoA of thiazolidinediones. Our
analysis show one or more underlying MoA for compounds and were well-substantiated with literature.
1 Introduction
Understanding protein target and oﬀ-target eﬀects of bioactive
compounds is a critical challenge in the field of drug discovery.
These eﬀects are of great importance as bioactive compounds
that indicate a certain therapeutic eﬀect could cause inadvertent
phenotypic eﬀects by binding to unexpected protein targets, thus
resulting in disruption of compound eﬃcacy.1 The mechanism of
action (MoA) of compounds could provide insight into inadvertent
phenotypic eﬀects. Although many attempts have been made to
understand MoA, this still remains a challenge in the field.2
Existing methods used to understand the MoA of compounds
involve analysing chemical structures, transcriptional responses
following treatment and text mining. Phenotypic readouts have
also been recently used to explore MoA.3,4 Studies by Young et al.
show that integrated analysis of phenotypic screening features
and ligand targets could identify MoA.5 Other studies scrutinizing
gene expression profiles also have given insight into drug MoA
and further prediction of drug targets.6 Applications using gene
expression profiles to observe several genes and signalling
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pathways concurrently enrich the understanding of underlying
mechanisms. Many researchers have focused their interest on
the delineation of gene expression profiles, in order to identify
those key genes and gene clusters whose expressions alter
disease state.7,8 These gene alteration patterns are identified
in order to underpin the mechanism of disease.
In order to experimentally determine gene expression variations
as described above, microarray techniques have been developed to
measure almost any change in biological activity that can be
reflected in an altered gene expression pattern.9,10 Using such
high-end technology, compound eﬀects can be measured to
provide extensive understanding on the eﬀect that genomic scale
alterations have at a cellular level. This technique is capable of
simultaneously providing information on the expression of a few
thousand genes at a time.11 Microarrays facilitate the discovery
of novel and unexpected functions of genes. This method is very
well established and has a wide range of applications such as the
identification of novel disease subtypes, development of new
diagnostic tools and identification of underlying mechanisms
of disease or drug response.12,13 In addition, gene expression
profiles also help in identifying therapeutic protein targets
understanding gene function, as well as establishing diagnostic,
prognostic and predictive markers of disease.14
Due to the advances in the genome studies, there is a wealth
of microarray data that has been deposited in public databases
such as Expression Atlas, which is a subset of ArrayExpress.15,16
Other public databases such as Connectivity Map (CMap)
consist of drug-like compounds tested for gene expression in
four cell lines. However, it is largely unknown how a compound
exactly modulates gene expression and only a few data analysis
approaches exist. One of the commonly used approaches
in comparing gene signatures is the Kolmogorov–Smirnov
statistical method, which was used in the CMap study.17,18
The CMap study aims to construct large libraries of drug and
gene signatures and provides a pattern-matching tool that
detects signature similarities in order to establish a relation-
ship between disease and therapeutic MoA. The libraries were
used to design the method that compares gene signatures to
diseases in the database and predict the connection; the MoA.
Due to the ability of finding connections and similarities
between the genes, disease and drugs, the results are termed
connectivity maps. The database consists of 1309 diverse
bioactive compounds on four different cell lines, where nearly
800 of the compounds are currently available in the market.17,18
Another study based on the CMap data was carried out by
Iorio et al., where they developed an automated approach to
exploit the similarity in gene expression profiles following drug
treatment. A drug network was constructed in order to relate
compounds based upon gene expression ranking from the
CMap tool. The drug MoA was determined based upon the
collective population3 Khan et al. and the hypothesis that
chemical structures of drugs (encoded in 3D) impact the drug
response. This resulted in specific patterns of gene expression,
which established a statistical relationship between the occur-
rences of patterns in both chemical and biological space.19 The
work of Gardner et al. shows that Genetic Networks and MoA of
compounds could be interpreted by gene expression profiles to
study the SOS pathway in Escherichia coli.20
Iskar et al. used the CMap data to analyse drug-induced
diﬀerential gene expression of drug targets in three cell lines.
Diﬀerent sets of drug features, such as chemical similarity and
Anatomical Therapeutic Chemical (ATC, based on therapeutic and
chemical properties of the compound MoA), were used to show
that homogeneous gene expression profiles were reliable with
mean centring. The chemical structural similarity, measured by
the tanimoto coeﬃcient, indicated that coeﬃcients greater than
0.85 show similar biological responses and tend to have similar
gene expression profiles. The same is also seen with compounds
that share the same ATC code. Furthermore, Iskar et al. quantified
the concept of a feedback loop using computationally normalized
data and scoring methods applicable to gene expression readouts.
From the Search Tool for Interactions of Chemicals (STITCH),
4849 CMap arrays and 40 656 drug target association provided
1290 drug-target relations.21,22 The studies also showed that
nearly 8% of the drug-induced targets were diﬀerentially regulated.
They also identified unknown drug-induced target expression
changes, some of which could be linked to the development of
drug tolerance in patients.6,23
In our study, we propose a new approach which aims to link
chemical space to protein target and gene expression space, thus
providing a better insight into the MoA of compound clusters. To
achieve this goal, there is a need for additional data from which
the link between compounds and protein target space can be
formed. Public chemogenomics databases such as ChEMBL and
PubChem contain large amounts of bioactivity data that aid in
machine learning approaches. These approaches extrapolate from
knowledge to classify new and orphan ligands for potential
protein targets, or oﬀ-targets, based upon the similarity of the
chemical structures. The target prediction algorithm based upon
the Nave Bayesian classifier was employed to predict probable
protein targets for compounds without target information
(Fig. 1).24,25 The resulting prediction provides each test com-
pound with probable protein targets and their respective scores,
representing the likelihood of binding to 477 protein targets.25,26
Target prediction approaches have been recently applied in a
Fig. 1 Target prediction overview. The orphan compound fingerprint infor-
mation is fed into the algorithm, which predicts the likelihood (score) of binding
to proteins based upon prior knowledge. This method establishes the link
between the compound and protein targets, further linking it to the MoA.
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variety of areas,27 such as the elucidation of MoA of compounds
used in traditional medicine (including ayurvedic and Chinese
medicine28) and are also used in examining ADR.29 However,
to the best of our knowledge, this is the first study employing
in silico target prediction in the context of gene expression data
analysis.
In addition, protein targets do not influence gene expression
changes directly; they work through signalling cascades. Pathway
databases provide information for linking genes and protein
targets. Databases such as KEGG and GO have been used in the
study to rationalise the findings.30 Repositories (KEGG and GO)
have information relating to a wide range of organisms, which
makes it flexible enough to integrate information from diﬀerent
databases and thus to study the functionality of recently dis-
covered genes.31 As shown in Fig. 2, the MoA relationships were
established in the following way; compound and gene expression
via microarray data, compound and protein target via the target
prediction algorithm and protein target and gene expression
(CMap) via pathway information. Hence, for a given gene
expression readout without knowledge of the protein targets
modulated, our approach gives an understanding into the MoA
of the compounds. By studying three particular clusters benzo-
quinone antineoplastic antibiotics, antipsychotic drugs and
antidiabetic and anti-inflammatory drugs, we were able to find
evidence of compounds perturbing certain genes and proteins
thus triggering one or more pathways. Hence, giving insights
into the possible MoA of the compounds.
2 Materials and methods
2.1 Gene expression data
2.1.1 The CMap dataset. The CMap dataset was extracted
from the Connectivity map server and consisted of 1309 drug-
like compounds with their respective genome-wide expression
profiles. In our study, the analysis for MCF7 (breast cancer
epithelial cell) and PC3 (human prostate cancer) cell lines,
containing 75 and 101 compounds respectively, were retained
after filtering for compounds administered for a duration of
6 hours and a maximum concentration of 10 mM.Whenmultiple
instances of compounds were found, the average gene expres-
sion level was used.
2.1.2 Pre-processing raw gene expression data. The extracted
gene-expression data was pre-processed using the Factor Analysis
for Robust Microarray Summarization (FARMS) method 1.8.2,32 by
separate arrayType/cellType combination. For an elaborate discus-
sion about the FARMS methods, we refer to Section S2.1 in the
ESI.† The log ratio was calculated per compound versus the vehicle.
If multiple vehicles were present in the dataset, the vehicle
closest to spatial median of all vehicles was used. The expres-
sion set was then filtered using informative/non-informative
calls (I/NI calls),33 where genes that were classified as non-
informative were excluded. Two types of arrays were used in the
experiment and thus only genes common to both arrays were
retained. Furthermore, only genes with abs(log ratio) 4 1 for
minimum 1 sample were kept.
2.2 Target prediction data
2.2.1 Target prediction algorithm. The target prediction
algorithm developed by Koutsoukas et al., is a probabilistic
machine learning algorithm for predicting protein targets of
bioactive molecules, which employs the Laplacian-modified
Nave Bayes classifier (NB). Chemical similarity is the underlying
principle of the method which is built on the approach that,
if compounds are similar in structural space they trigger similar
targets. Compounds structural features (Extended Connectivity
Fingerprints 4) are used as molecular descriptors. The NB
classifier can be illustrated using the following equation.26
PðC ¼ ojD ¼ f Þ ¼ PðD ¼ f jC ¼ oÞPðC ¼ oÞðPðD ¼ f ÞÞ
 
In this equation, the probability of a compound belonging to
class o given descriptor f is calculated. P(C = o) is the priori
probability of class o and P(D = f ) is a priori probability of the
features, f. P(D = f |C = o), is the key value in this equation,
which is the likelihood of the feature f given the class o. This
probability is estimated by the NB classifier from the training set
(discussed below), which assumes that the features are indepen-
dent of each other for a given class. It has been observed before
that the NB classifier is still an eﬀective classifier in cases where
features are correlated. In machine learning practices, a training
set is employed for the classifier to learn from the examples and
make predictions for the unseen dataset; the test set. The classifier
is trained on a large benchmark dataset of bioactive compounds
retrieved from the publicly available ChEMBL database, which is a
repository of small bio-active molecules extracted from scientific
literature. The training dataset covers 477 human protein targets
with around 190000 protein–ligand associations, based upon the
reported bioactivities (Ki/Kd/IC50/EC50) being equal or better than
10 mM with a confidence score of 8 or 9. These rules for extracting
compounds ensured reliable compound-target associations for
training the model. The target prediction algorithm performance
was evaluated by 5-fold cross validation.26
Fig. 2 Mechanism of action of a compound. The compound to protein
target information is derived from the target prediction algorithm and the
phenotypic gene expression information is curated from experimentally
annotated data. To complete the triangle, KEGG and GO pathway infor-
mation is annotated for the genes and proteins and are overlapped to find
similar pathways.
Molecular BioSystems Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
Se
pt
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
4/
04
/2
01
5 
11
:1
4:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Mol. BioSyst., 2015, 11, 86--96 | 89
2.2.2 Predicted protein binding probability scores. The out-
put file of the target prediction algorithm for a given compound
is a list of ChEMBL protein targets and a score quantifying the
compound’s binding likelihood to the target. The rank is based
on the likelihood (NB score) of a query compound being active
against each of the protein targets. With this data, target
prediction matrix scores for the 76 and 101 compounds for
the 2 cell lines (MCF7 and PC3 respectively) were generated for
all the available protein targets.
2.2.3 Data binarisation. Although it is common to use
empirically derived global score cut-oﬀs for bioactivity predic-
tions, in this approach class-specific confidence score cut-oﬀs
were calculated internally in order to increase the accuracy of
our predictions.34 These compound bioactivity profiles were
represented as a binary matrix, where 1 represents a likelihood
of compound binding to the protein target and 0 represents
otherwise, with respect to the individual score cut-oﬀs.
2.3 Clustering of compounds
The first stage of analysis comprises the clustering of compounds
into groups exhibiting a high degree of both intra-cluster similarity
and inter-cluster dissimilarity, according to the target prediction
scores. The distance between compounds was based upon the
Tanimoto coeﬃcient, which is a widely used and well-established
distance measure for binary values.35 Our implementation is an
agglomerative hierarchical clustering approach. Each compound
is absorbed into increasingly large clusters until the dataset is
expressed as a single cluster composed of all compounds. The
previously generated binary profile matrix was then used to
compute the similarity between each compound bioactivity
profile. The hierarchical clustering method employed here
generates strictly nested structures, which can be presented
graphically using dendrograms.
2.4 Feature selection
Feature selection was performed by applying Fisher’s exact test,
target-by-target, with the given cluster of compounds as one
group and the rest of compounds as the other group. To
integrate the gene expression data in the analysis, genes that
were regulated by a particular cluster of compounds of interest
were chosen.36 The Linear Models for Microarray Data (Limma)
method was used to assess diﬀerential expression.37,38
The Benjamini–Hochberg false discovery rate (BH-FDR)
method was used to adjust for multiplicity. Protein targets
and genes were ranked based upon their adjusted p-values.39
2.5 Pathway analysis
Once the lists of genes and protein targets had been obtained,
a pathway analysis was conducted in order to interpret the
biological function of the selected subset of genes/protein
targets.
2.5.1 Overlapping pathway search using KEGG and GO
databases. Pathway information was extracted from the KEGG
and GO databases for the gene sets and protein targets involved
in our study.30 The protein targets and gene sets together with their
pathways were used as input for the pathway-oriented approach.40,41
Interesting sets of genes and protein targets from a particular cluster
were then examined for common pathways. Identification of over-
lapping pathway(s) enables biological interpretation of the results.
This pathway-oriented approach does not involve any statistical
analysis and is dependent on the quality of information available in
both databases.
2.5.2 Gene set analysis usingmean log p-value (MLP) analysis.
MLP analysis, in contrast with the pathway search presented in the
previous section, does not involve pre-selection of genes prior to
the analysis. Genes are categorized into gene sets according to
their functional relationship. A gene set is most likely significant
if many of the genes comprising that set have small p-values
obtained from the test of diﬀerential expression. Our algorithm uses
the LIMMA test statistics for this, as discussed in Section 2.4.42–44
The MLPmethod can be used to identify which biological pathways
appear to be most affected and their interconnections may be
visualised using a GO graph. More details about the MLP
method is given in the Section S2.2 (ESI†).
3 Results and discussion
The hierarchical clustering of compounds according to the
similarity of their target prediction profiles, based upon the
477 ChEMBL targets, is presented in Fig. 3 for the MCF7 and
PC3 cell lines. Several interesting target-based compound clus-
ters (with Tanimoto coeﬃcient 4 0.5) are identified in each
cell line; 8 from MCF7 and 11 from PC3 (numbered in their
respective heatmaps). The target prediction data depends upon
the structural make-up of the compounds; hence a compound
cluster observed in one cell line will also hold for another line,
given that all member compounds are present in both cell
lines. This is the case for cluster 3 of MCF7 and cluster 4 of PC3,
which contain the same set of compounds; estradiol, alpha-
estradiol and fulvestraat. The number of predicted targets
found for each compound present in MCF7 and PC3 cell lines
is shown in Fig. S1 (ESI†).
This study hypothesises that compounds stimulating similar
targets will also trigger similar genes and pathways. Each
compound set is expected to be associated with a number of
genes (diﬀerentially expressed between the subset of com-
pounds in the cluster and the rest of the compounds in the
set). In this paper, heatmaps and volcano plots are used for
the visualisation of predicted active protein targets and diﬀer-
entially expressed genes, respectively, for a given compound
cluster of interest.
In the next step, pathway analysis is used to deduce the MoA
of the compound cluster. Many statistical approaches have
been developed for pathway analysis.45 For the analysis pre-
sented in this paper, two approaches have been used; the first is
a pathway-oriented approach in which KEGG and GO pathways
are retrieved for the gene and protein target sets for sub-
clusters of interest and common pathways are studied; and
the second is gene set enrichment analysis using MLP in which
the focus is on coordinated diﬀerential expression of a set of
functionally related genes.
Paper Molecular BioSystems
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
Se
pt
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
4/
04
/2
01
5 
11
:1
4:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
90 | Mol. BioSyst., 2015, 11, 86--96 This journal is©The Royal Society of Chemistry 2015
This analysis flow is illustrated for 3 of the 19 identified
clusters in the following sections. Results for the other homo-
geneous target-prediction-based sub-clusters are summarised in
Tables S1 for MCF7 and S2 for PC3 (ESI†). The MoA for 6 of the
8 MCF7 clusters and 6 of the 11 PC3 clusters, are established
using our integrated approach.
3.1 Benzoquinone antineoplastic antibiotic
3.1.1 Associating genes with compounds. The first compound
cluster studied consists of the compounds geldanamycin and
tanespimycin from cluster 7 of the MCF7 cell line. Both compounds
are benzoquinone antineoplastic antibiotics, which are used to
inhibit the function of heat shock protein 90 (HSP90).46,47 In Fig. 4
the top diﬀerentially expressed genes between these 2 compounds
and other compounds in the set are displayed. Gene HSPA1B shows
a perturbation of an above 2-fold change in both the compounds
and also shows a log(P-value) greater than 50 in the volcano plot
(Fig. 4). The HSP90AB1 gene shows a fold change above 1.2 in both
the compounds and was found to be statistically significant. Other
genes such as HSPA6, HSPA4L, DNAJB4, HSPH1 were all found to be
statistically significant with a fold change above 1. Literature shows
that protein HSP90 is encoded by the HSP90AB1 gene.48 The
compounds are seen to perturb similar type of genes, thus showing
that clustering compounds based upon targets is useful in bringing
compounds of similar therapeutic class together.
3.1.2 Associating protein targets to compounds. The clus-
tering of compounds based upon protein target similarity is
presented in Fig. 5a, highlighting the cluster of geldanamycin
and tanespimycin. This clustering is identical to that presented
in Fig. 3a, with geldanamycin and tanespimycin as cluster 7.
Fig. 3 Heatmaps with dendrograms showing compound similarity scores based upon protein target prediction data for the (a) MCF7 and (b) PC3 cell
lines. The colour is scaled such that darker colours represent increased similarity among the compounds, while similarities below the 90th percentile are
represented in white. Compound clusters with high Tanimoto coeﬃcient (40.5) are identified and numbered in the heatmaps, leading to 8 subclusters
for MCF7 and 11 clusters for PC3. Subcluster 3 of MCF7 and subcluster 4 of PC3 cell line represent the same set of 22 compounds present in both the
datasets. Given that these compounds share similar predicted protein targets, they form defined therapeutic type sub-clusters.
Fig. 4 Volcano plotlog(P-value) vs. fold change. Every gene is represented
by a dot in the graph. Genes HSPA6, HSPA4L, DNAJB4 and HSPH1 at the top
have the smallest P-values (i.e. the highest evidence for statistical significance)
when testing for diﬀerentially expressed genes between the cluster of interest
and other compounds in the set. Genes at the left and right-hand sides of the
graph have the largest eﬀect size (fold-change). The HSP-related genes for
sub-cluster containing benzoquinone antineoplastic antibiotic compounds in
the plot are seen to be highly significant, thus suggesting their role in the MoA
of these compounds.
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Fig. 5b represents the set of protein targets that are likely to
bind to these two compounds, based upon the results from
protein-target prediction. The expression profile plot for the top
diﬀerentially expressed genes of this compound cluster clearly
shows these two compounds induce a relatively higher expres-
sion than the rest (Fig. 5c). The ordering of compounds in the
x-axis is the same for all plots. The top 5 protein targets are
transcription factor AP-1 (AP-1), transient receptor potential
cation channel subfamily V member 1 (TPCC), tyrosine protein
kinase BTK (BTK), heat shock protein HSP90 alpha (HSP90),
protein kinase C zeta type (PKCZ) and G-protein coupled
receptor 55 (GPCR).
3.1.3 Using pathways to understand MoA. Identification of
the protein targets and genes regulated by the compounds can
already provide information about the MoA. However, searching
for the pathway(s) can provide a deeper insight, or more inter-
pretable information, compared to a short list of potentially
functionally-unrelated protein targets and genes. This qualitative
search of common pathways between targets and genes is
dependent upon the completeness of the KEGG and GO pathway
databases (see Tables S1 and S2, ESI†). As a consequence, a lack
of completeness may return empty results.
In the studied cluster, the pathway ‘‘response to the unfolded
protein’’ (GO:006986) was found to be an overlapping pathway
involving the predicted protein target heat shock protein HSP90
alpha and the genes HSP90AB1, HSPA6, HSPA4L, DNAJB4, HSPA1B
and DNAJB1. Literature has also shown that HSP90 inhibition
is associated with the activation of unfolded protein response.
Fig. 5 Genes and protein targets regulated by compounds geldenamycin and tanespimycin. (a) Protein-target similarity-based hierarchical clustering of
compounds; (b) heatmap of the proteins target (rows) and compounds(columns) coloured according to activation/inactivation of protein targets; (c) the
profile plot of the top diﬀerentially expressed genes with compounds ordered according to (a) in the x-axis and fold-change in the y-axis. The selected
compound sub-cluster contains the only compounds that predicted the targets represented in blue. Thus, some genes are particularly perturbed
with respect to the sub cluster selected. The targets are transcription factor AP-1 (AP-1), transient receptor potential cation channel subfamily V
member 1 (TPCC), tyrosine protein kinase BTK (BTK), heat shock protein HSP90 alpha (HSP90), protein kinase C zeta type (PKCZ) and G-protein coupled
receptor 55 (GPCR). The genes (HSP90AB1, HSPA6, HSPA4L, DNAJB4, HSPH1, HSPA1B, ADCY7 and AHSA1) studied here do not have high perturbation
for other compounds, suggesting the hypothesis that the targets and the genes are linked.
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Moreover, the compound geldanamycin is a known inhibitor of
HSP90, thus modulating the unfolded protein response.49
Similarly, the overlap between HSP protein and the genes
HSP90B1, HSPA1B, HSPA1A and HSP90AA1 show response to
the KEGG pathway ‘‘antigen processing and presentation’’. The
genes and proteins in the overlap are known to be involved in
these pathways (Table S1, ESI†). A study carried out by Albert50
also supports our finding that HSP plays a role in antigen
processing and presentation, where these proteins are released
during cell death in order to bind to cell surface receptors of the
antigen-presenting cells (Table 1).
3.1.4 Gene set enrichment analysis using the mean minus
logp-value (MLP) method. GO and KEGG public pathway data-
bases lack updated annotations from the literature.51 MLP
analysis bridges this gap by identifying significantly aﬀected
biological processes or gene sets consisting of functionally
related genes. The top 5 set of significant GO terms according
to their structure in the ontology are displayed in Fig. 6. The MLP
results agree with those from the pathway search and literature
on the pathway ‘‘response to unfolded protein’’, which is on the
top gene set in the analysis.49 The pathway search provides
information on known existing gene-pathway links, whereas
MLP analysis shows statistically enriched pathways that are
significant (with or without available literature evidence). While the
pathway search makes use of top diﬀerentially expressed genes,
providing 5 genes linked to this pathway, the MLP analysis can
provide an enriched set of genes biologically linked through the
‘‘response to unfolded protein’’ pathway. Using the LIMMA
p-values as the input, the HSP and DNAJ-related genes are
shown to dominate this gene set (Fig. 7).
The MLP method therefore provides statistically significant
genes and also the significance of each gene in the pathway
of interest. The gene set enrichment analysis is a good start
when there is limited pathway information, in understanding
the MoA of compounds.
3.2 Antipsychotic drugs
A cluster based on the MCF7 cell line consists of well-known
antipsychotic drugs (amitriptyline, clozapine, thioridazine, chlor-
promazine, trifluoperazine, prochlorperazine and fluphenazine),
which share the predicted protein targets muscarinic, histamine,
dopamine and adrenergic receptors and cytochrome P450 2D6
(Fig. S3, ESI†). Antipsychotics drugs are known to be promiscuous
therefore identifying selective protein targets are diﬃcult.52 Fig. S2
(ESI†) displays the top genes regulated by the compounds which
include genes INSIG1, IDI1, SQLE, MSMO1, etc. The protein target
CYP2D6, a member of the enzyme family Cytochromes P450
(CYP), is known to metabolise drugs53 and to play a key role
in the synthesis of steroid, cholesterol and prostacyclins.54,55
Table 1 Overlapping pathways. Pathway search involving the top protein
targets and genes regulated by the compounds geldenamycin and tanespimycin
Pathway Target Genes
Response to
unfolded protein
Heat shock
protein 90 alpha
HSP90B1
HSPA6
HSPA4L
DNAJB4
HSPA1B
Antigen processing
and presentation
Heat shock
protein 90 alpha
HSP90B1
HSPA1B
HSPA1A
HSP90AA1
Fig. 6 GO pathways containing the top 5 gene sets with MLP for benzo-
quinone antineoplastic antibiotic compounds. Every ellipse represents a gene
set. The colour indicates the significance: the darker, themore significant. The
connectors indicate that the gene sets are related. The lower the GO term is
in the graph, the more specific is the gene set.
Fig. 7 Significance plot of top functionally related genes contributing in
the pathways ‘‘response to unfolded proteins’’. The plot represents the top
15 genes contributing with the level of significance in the bar for the respective
pathways in the MLP analysis for geldanamycin and tanespimycin compound
cluster. The height of a bar represents log10(geneStatistic) of the gene
indicated on the y-axis. Unlike the overlap method for pathways search, which
uses a short list of annotated genes and targets, MLP makes use of all the
p-values obtained from LIMMA analysis to identify gene sets enriched in
small p-value. In this case, MLP results agree with the overlap pathway
method and therefore can be used where genes and targets are not
annotated with pathways in KEGG and GO.
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Literature studies have shown that CYP2D6 greatly influences
the metabolism of antipsychotics drugs.56 Pathway analysis
information was also added to relate the MoA of the anti-
psychotics. A search of an overlapping pathway was executed
on the antipsychotic cluster, where genes INSIG-1, LDLR and
protein target CYP2D6 were observed to overlap with ‘‘steroid
metabolic process pathway’’. This observation complies with
the study by Polymeropoulos et al., in which it was shown that
genes INSIG-1 and LDLR were up-regulated by antipsychotic
drugs that also influenced the steroid biosynthesis.57 While
these genes show significance for the antipsychotic drugs, they
remain unperturbed for the other compound sub-clusters. The
neighbouring compound cluster (verapamil and dexverapamil)
of calcium channel binders are known to have antipsychotic
eﬀects, thus large numbers of similar targets are predicted.58,59
The genes (IDI1, SQLE, MSMO1, INSIG1, MNT, SRSF7, HMGCS1
and CCR1) also have similar gene perturbation on this sub-cluster.
Furthermore, MLP indicated that the ‘‘steroid metabolic
process’’ pathway was significantly enriched in the antipsychotic
sub-cluster. Enrichment was also observed for the pathways
‘‘cholesterol biosynthesis process’’, ‘‘sterol biosynthesis process’’,
‘‘cholesterol metabolic process’’, ‘‘sterol metabolic process’’ and
‘‘steroid biosynthesis process’’ (Fig. S4, ESI†). The gene Dhcr24,
as shown in the Fig. S5 (ESI†), is predicted to be highly significant
on the ‘‘cholesterol biosynthetic process’’ and is known to code
for the protein cholesterol-synthesizing enzyme seladin-1, which
agrees with the study by Crameri et al.60,61 Another gene in the
list, G6PD, was also known to regulate the pathway through
protein sterol regulatory element-binding proteins (SREBP).62
Studies by Iskar et al. have shown that the genes LDLR, INSIG1,
IDI1, SQLE and HMGCS1 are responsible for the ‘‘cholesterol
metabolic process’’23 (Fig. S5, ESI†), which is in accordance
with our results. As stated by Polymeropoulos et al. ‘‘activation
of antipsychotics by genes associated with lipid homeostasis is
not just a common oﬀ-target eﬀect of these drugs but rather the
common central mechanism by which they achieve their anti-
psychotic activity.’’57
In the compounds clustered based upon protein target
similarity, compounds verepamil and dexverepamil shared protein
targets such as the hydroxytryptamine receptor, the adrenergic
receptor, the histamine H1 receptor, the dopamine receptor and
the muscarinic acetylcholine receptor M4. Although they share
similar protein targets, the intensity of gene expression profiles
were diﬀerent indicating that the method can clearly distinguish
between close sub-clusters and thus suggesting diﬀerences in their
MoA. SREBP and cholesterol-synthesizing enzyme seladin-1 were
not predicted by the target prediction algorithm, as they were out
of the applicability domain.
3.3 Antidiabetic and anti-inflammatory drugs
A PC3 cell line cluster (Table S2, ESI†) comprising of thiazol-
idinediones (rosiglitazone and troglitazone drugs) was found
to have both antidiabetic and anti-inflammatory eﬀects.63,64
In silico target prediction algorithm indicated that these com-
pounds were likely to bind to the peroxisome proliferator
activated receptor gamma (PPAR-gamma), peroxisome proliferator
activated receptor alpha (PPAR-alpha) and acyl CoA desaturase.
Spiegelman has shown the MoA of antidiabetic thiazolidinediones
to induce activation of PPAR gamma and thus regulate genes
involved in glucose and lipid metabolism.65 Gene expression
profiles of genes FABP4 and ANGPTL4 have fold changes of
3 and 1 respectively. Studies have shown that antidiabetic
thiazolidinediones are ligands for the nuclear receptor PPAR,
which exert their anti-hyperglycaemic eﬀects by regulation of
the PPAR responsive genes and also that gene FABP4 is rapidly
up-regulated upon PPAR gamma ligand administration; this
confirms our finding of this gene showing high fold change.15,66 A
study by Pal et al. showed that the gene ANGPTL4 is responsible
for epidermal diﬀerentiation mediated via the PPAR protein.67
During overlap pathway analysis, genes FABP4 and ANGPTL4
were found to share pathway ‘‘PPAR signalling’’ with proteins PPAR-
gamma, PPAR-alpha and acyl CoA desaturase. Confirming our
observation, antidiabetic thiazolidinediones in pathway hsa03320
of the KEGG database induce ‘‘PPAR signaling pathway’’ by
perturbing genes FABP4 and ANGPTL4 and PPAR proteins. This
indicates that the MoA of antidiabetic thiazolidinediones involves
PPAR signalling.
There was overlap of the pathway ‘‘induction of apoptosis’’
with gene PRKCD and protein target PPAR-gamma. In the study
by Heath2008, thiazolidinediones were shown to have potential
for inducing apoptosis in cancer cells by binding to protein
PPAR-gamma.68 In our study on thiazolidinediones, we also
observed that gene PRKCD is down-regulated substantially when
compared to other compounds in the dataset showing selectivity
for this particular gene. Hence suggesting gene PRKCD to be
involved in the MoA for thiazolidinediones.
3.4 Other compound clusters
Of the 8 and 11 compound clusters identified in the respective
MCF7 and PC3 cell lines, our approach was able to link the genes
and targets via pathway(s) for 6 compound clusters in each cell
line. Some of the links (compound-genes, compound-target
and genes-pathway-target), however, lacked literature support
(Tables S1 for MCF7 and S2 for PC3, ESI†). The target predic-
tion similarity data also produces many singletons, which are
compounds that do not share any targets with remaining com-
pounds in the set, thus providing a limited number of clusters
to be investigated.
4 Conclusions
Combining target-based compound similarity with corresponding
gene expression information provides a better understanding
of compound cluster behaviour, both on the bioactivity level
and on the transcriptional level. Ideally, any target-driven
compound cluster can be investigated using this analysis
flow, but it is more logical to prioritize clusters with com-
pounds that share at least half of the targets. This compound
cluster selection requires choosing an arbitrary cut-oﬀ for the
Tanimoto similarity score, which is 0.5 in this case. Studies
by Hert et al. and Martin et al. show mean nearest neighbour
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similarity across diﬀerent activity classes are between 0.3
and 0.7, and therefore 0.5 is a reasonable value to describe
similarity.69,70 Increasing this cut-oﬀ value would mean filter-
ing out other compound clusters for the next level of analysis,
while decreasing this value would allow for more compound
clusters to be analysed. However, in practice, the choice largely
depends on which compound sets are of most interest to the
researcher.
Analysis was performed upon all selected homogeneous
target-driven compound clusters, but focus was placed on the
MoA of three compound clusters; benzoquinone antineoplastic
antibiotics, antipsychotic drugs and antidiabetic and anti-
inflammatory drugs.
Analysis of the benzoquinone antineoplastic antibiotic drug
sub-cluster gave insight into their MoA through the HSP genes
and the HSP90-alpha protein. Further pathway study directed
us to the underlying MoA though ‘‘antigen processing and
presentation’’ and ‘‘response to the unfolded protein’’. In the
sub-cluster study of antipsychotic drugs, our integrated approach
was able to narrow down the MoA of the compound to protein
target CYP2D6 and genes INSIG-1 and LDLR. In addition, the
pathway analysis confirmed the MoA through ‘‘steroid metabolic
process pathway’’. Furthermore, in the antidiabetic and anti-
inflammatory drugs sub-cluster, the MoA of the compounds
was found to involve genes FABP4 and ANGPTL4 and protein
PPAR and pathway analysis confirmed ‘‘PPAR signalling’’ as
being involved in the underlying MoA of these compounds. All
these analysis were confirmed by literature evidence. Note that
these studied compound clusters (antipsychotic drugs, anti-
diabetic and anti-inflammatory drugs) along with other CMap
compounds, were selected to represent a broad range of acti-
vities not necessarily related to oncology, and were profiled only
in cancer cell lines due to practical limitations. An assessment
of the extent of the results to be cell line specific is therefore not
feasible here.
Although a large amount of information is present in public
databases, KEGG and GO lack annotations.51 MLP analysis thus
provided the statistical information required to enrich genes
in the pathways of interest. This approach enabled us to gain
valuable insight into known MoA of compounds and also pro-
vides a means by which new (or previously unestablished) MoA
can be discovered.
This paper therefore presents a pragmatic approach to
dataset integration, involving relatively few stages of statistical
analysis. The method was designed to capture the diﬀerent
associations (if they exist) between compounds, genes and
targets, in order to gain insight regarding the MoA of com-
pounds. This approach is not only limited to the use of
gene expression and target prediction data, however; the tech-
nique can be more generally used to find links between two
datasets measured against the same set of observations.
The technique may also be improved by integrating more
sophisticated similarity functions, which could more accurately
predict the clustering of compounds based upon the aﬃnity
to common targets and thus provide an even more powerful
predictive tool.
Acknowledgements
We would like to gratefully acknowledge the Institute for the
Promotion of Innovation by Science and Technology in Flanders
(IWT) for providing us with the O&O grant 100988: QSTAR –
Quantitative structure transcriptional activity relationship. We
would like to thank IWT and Janssen Pharmaceutica NV for
jointly funding PhD projects of Aakash Chavan Ravindranath
and Nolen Perualila-Tan. Ziv Shkedy and Nolen Perualila-Tan
gratefully acknowledge the support from the IAP Research Network
P7/06 of the Belgian State (Belgian Science Policy). Georgios Drakakis
thanks Lilly and EPSRC for funding his PhD. Sonia Liggi and Daniel
Mason thanks Unilever for funding. Dr Andreas Bender thanks
Unilever for funding and the European Research Council for a
Starting Grant (ERC-2013-StG-336159 MIXTURE).
References
1 M. L. MacDonald, J. Lamerdin, S. Owens, B. H. Keon, G. K.
Bilter, Z. Shang, Z. Huang, H. Yu, J. Dias and T. Minami,
et al., Nat. Chem. Biol., 2006, 2, 329–337.
2 S. Tian, Y. Li, D. Li, X. Xu, J. Wang, Q. Zhang and T. Hou,
J. Chem. Inf. Model., 2013, 53, 1787–1803.
3 F. Iorio, R. Tagliaferri and D. di Bernardo, J. Comput. Biol.,
2009, 16, 241–251.
4 Y. Feng, T. J. Mitchison, A. Bender, D. W. Young and J. A.
Tallarico, Nat. Rev. Drug Discovery, 2009, 8, 567–578.
5 D. W. Young, A. Bender, J. Hoyt, E. McWhinnie, G.-W.
Chirn, C. Y. Tao, J. A. Tallarico, M. Labow, J. L. Jenkins
and T. J. Mitchison, et al., Nat. Chem. Biol., 2007, 4, 59–68.
6 M. Iskar, M. Campillos, M. Kuhn, L. J. Jensen, V. van Noort
and P. Bork, PLoS Comput. Biol., 2010, 6, e1000925.
7 M. Maienschein-Cline, J. Zhou, K. P. White, R. Sciammas
and A. R. Dinner, Bioinformatics, 2011, 28, 206–213.
8 D. N. Arnosti and M. M. Kulkarni, J. Cell. Biochem., 2005, 94,
890–898.
9 A. L. Tarca, R. Romero and S. Draghici, Am. J. Obstet.
Gynecol., 2006, 195, 373–388.
10 D. Amaratunga, J. Cabrera and Z. Shkedy, Exploration and
Analysis of DNA Microarray and Other High-Dimensional Data,
Wiley, 2nd edn, 2014.
11 P. Breyne, R. Dreesen, B. Cannoot, D. Rombaut, K. Vandepoele,
S. Rombauts, R. Vanderhaeghen, D. Inze´ and M. Zabeau,
Mol. Genet. Genomics, 2003, 269, 173–179.
12 T. D. Gallardo, G. B. John, L. Shirley, C. M. Contreras, E. A.
Akbay, J. M. Haynie, S. E. Ward, M. J. Shidler and D. H.
Castrillon, Genetics, 2007, 177, 179–194.
13 X. Li, S. Rao, Y. Wang and B. Gong, Nucleic Acids Res., 2004,
32, 2685–2694.
14 D. Nikolova, H. Zembutsu, T. Sechanov, K. Vidinov, L. Kee,
R. Ivanova, E. Becheva, M. Kocova, D. Toncheva and
Y. Nakamura, Oncol. Rep., 2008, 20, 105–121.
15 M. Kapushesky, T. Adamusiak, T. Burdett, A. Culhane,
A. Farne, A. Filippov, E. Holloway, A. Klebanov, N. Kryvych
and N. Kurbatova, et al., Nucleic Acids Res., 2011, 40,
D1077–D1081.
Molecular BioSystems Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
Se
pt
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
4/
04
/2
01
5 
11
:1
4:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Mol. BioSyst., 2015, 11, 86--96 | 95
16 A. Brazma, H. Parkinson, U. Sarkans, M. Shojatalab,
J. Vilo, N. Abeygunawardena, E. Holloway, M. Kapushesky,
P. Kemmeren, G. G. Lara, A. Oezcimen, P. Rocca-Serra and
S.-A. Sansone, Nucleic Acids Res., 2003, 31, 68–71.
17 J. Lamb, E. D. Crawford, D. Peck, J. D. Modell, I. C. Blat,
M. J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K. N.
Ross, M. Reich, H. Hieronymus, G. Wei, S. Armstrong, S. J.
Haggarty, P. A. Clemons, R. Wei, S. A. Carr, E. S. Lander and
T. R. Golub, Science, 2006, 313, 1929–1935.
18 J. Lamb, Nat. Rev. Cancer, 2007, 7, 54–60.
19 S. A. Khan, A. Faisal, J. P. Mpindi, J. A. Parkkinen,
T. Kalliokoski, A. Poso, O. P. Kallioniemi, K. Wennerberg
and K. Samuel, BMC Bioinf., 2012, 13, 1471–2105.
20 T. S. Gardner, D. di Bernardo, D. Lorenz and J. J. Collins,
Science, 2003, 301, 102–105.
21 M. Kuhn, C. von Mering, M. Campillos, L. J. Jensen and
P. Bork, Nucleic Acids Res., 2008, 36, D684–D688.
22 M. Kuhn, D. Szklarczyk, A. Franceschini, M. Campillos,
C. von Mering, L. J. Jensen, A. Beyer and P. Bork, Nucleic
Acids Res., 2010, 38, D552–D556.
23 M. Iskar, G. Zeller, P. Blattmann, M. Campillos, M. Kuhn,
K. H. Kaminska, H. Runz, A.-C. Gavin, R. Pepperkok,
V. van Noort and P. Bork, Mol. Syst. Biol., 2013, 9, 662.
24 T. Klabunde, Br. J. Pharmacol., 2007, 152, 5–7.
25 A. Koutsoukas, B. Simms, J. Kirchmair, P. J. Bond,
A. V. Whitmore, S. Zimmer, M. P. Young, J. L. Jenkins,
M. Glick, R. C. Glen and A. Bender, J. Proteomics, 2011, 74,
2554–2574.
26 A. Koutsoukas, R. Lowe, Y. Kalantarmotamedi, H. Y. Mussa,
W. Klaﬀke, J. B. O. Mitchell, R. C. Glen and A. Bender,
J. Chem. Inf. Model., 2013, 53, 1957–1966.
27 B. Chen, K. J. McConnell, N. Wale, D. J. Wild and
E. M. Giﬀord, Bioinformatics, 2011, 27, 3044–3049.
28 F. Mohd Fauzi, A. Koutsoukas, R. Lowe, K. Joshi, T.-P. Fan,
R. C. Glen and A. Bender, J. Chem. Inf. Model., 2013, 53, 661–673.
29 M. Takarabe, M. Kotera, Y. Nishimura, S. Goto and
Y. Yamanishi, Bioinformatics, 2012, 28, i611–i618.
30 H. Ogata, S. Goto, K. Sato, W. Fujibuchi, H. Bono and
M. Kanehisa, Nucleic Acids Res., 1999, 27, 29–34.
31 L. du Plessis, N. Skunca and C. Dessimoz, Briefings Bioinf.,
2011, 12, 723–735.
32 S. Hochreiter, D.-A. Clevert and K. Obermayer, Bioinformatics,
2006, 22, 943–949.
33 W. Talloen, D. Clevert, S. Hochreiter, D. Amaratunga,
L. Bijnens, S. Kass and H. Go¨hlmann, Bioinformatics, 2007,
23, 2897–2902.
34 G. V. Paolini, R. H. B. Shapland, W. P. van Hoorn, J. S. Mason
and A. L. Hopkins, Nat. Biotechnol., 2006, 24, 805–815.
35 P. Willett, J. Barnard and G. Downs, J. Chem. Inf. Model.,
1998, 38, 983–996.
36 R. A. Fisher, J. Roy. Statist. Soc., 1922, 85, 87–94.
37 G. K. Smyth, J. Michaud and H. S. Scott, Bioinformatics,
2005, 21, 2067–2075.
38 G. K. Smyth, Stat. Appl. Genet. Mol. Biol., 2004, 3, 397–420.
39 Y. Benjamini and Y. Hochberg, J. Roy. Statist. Soc. Ser. B,
1995, 57, 289–300.
40 S. Liggi, G. Drakakis, A. E. Hendry, K. M. Hanson,
S. C. Brewerton, G. N. Wheeler, M. J. Bodkin, D. A. Evans
and A. Bender, Mol. Inf., 2013, 32, 1009–1024.
41 S. Liggi, G. Drakakis, A. Koutsoukas, I. CortesCiriano,
P. MartnezAlonso, T. E. Malliavin, A. Velazquez-Campoy,
S. C. Brewerton, M. J. Bodkin, D. A. Evans, R. C. Glen,
J. A. Carrodeguas and A. Bender, Future Med. Chem., 2013,
DOI: 10.1186/1758-2946-5-S1-P15.
42 N. Raghavan, D. Amaratunga, J. Cabrera, A. Nie, J. Qin and
M. McMillian, J. Comput. Biol., 2006, 13, 798–809.
43 N. Raghavan, A. De Bondt, W. Talloen, D. Moechars,
H. W. H. Go¨hlmann and D. Amaratunga, Bioinformatics,
2007, 23, 3032–3038.
44 D. Lin, Z. Shkedy, D. Yekutieli, D. Amaratunga and
L. Bijnens, Modeling Dose-response Microarray Data in Early
Drug Development Experiments Using R, Order Restricted
Analysis of Microarray Data, Springer, 2012.
45 H. Go¨hlmann and W. Talloen, Gene Expression Studies Using
Aﬀymetrix Microarrays, Chapman and Hall/CRC, 2009,
pp. 1314–1315.
46 S. Modi, A. Stopeck, H. Linden, D. Solit, S. Chandarlapaty,
N. Rosen, G. D’Andrea, M. Dickler, M. E. Moynahan,
S. Sugarman, W. Ma, S. Patil, L. Norton, A. L. Hannah and
C. Hudis, Clin. Cancer Res., 2011, 17, 5132–5139.
47 T. Taldone, A. Gozman, R. Maharaj and G. Chiosis, Curr.
Opin. Pharmacol., 2008, 8, 370–374.
48 B. Chen, W. H. Piel, L. Gui, E. Bruford and A. Monteiro,
Genomics, 2005, 86, 627–637.
49 E. L. Davenport, H. E. Moore, A. S. Dunlop, S. Y. Sharp,
P. Workman, G. J. Morgan and F. E. Davies, Blood, 2007,
110, 2641–2649.
50 M. L. Albert, Nat. Rev. Immunol., 2004, 4, 223–231.
51 P. Khatri, M. Sirota and A. J. Butte, PLoS Comput. Biol., 2012,
8, e1002375.
52 J. Brown and Y. Okuno, Chem. Biol., 2012, 19, 23–28.
53 T. Lynch and A. Price, Am. Fam. Physician, 2007, 76, 391–396.
54 D. W. Nebert and D. W. Russell, Lancet, 2002, 360, 1155–1162.
55 J. B. Schenkman, J. Steroid Biochem.Mol. Biol., 1992, 43, 1023–1030.
56 P. Dorado, R. Berecz, E. Peas-Lled, M. Cceres and A. Llerena,
Curr. Drug Targets, 2006, 7, 1671–1680.
57 M. H. Polymeropoulos, L. Licamele, S. Volpi, K. Mack,
S. N. Mitkus, E. D. Carstea, L. Getoor, A. Thompson and
C. Lavedan, Schizophr. Res., 2009, 108, 134–142.
58 B. Umukoro, Afr. J. Med. Med. Sci., 2010, 39, 61–66.
59 G. Palit, A. Kalsotra, R. Kumar, C. Nath and M. P. Dubey,
Eur. J. Pharmacol., 2001, 421, 139–144.
60 A. Crameri, E. Biondi, K. Kuehnle, D. Lu¨tjohann, K. M.
Thelen, S. Perga, C. G. Dotti, R. M. Nitsch, M. H. Mohajeri
and M. D. Ledesma, EMBO J., 2006, 25, 432–443.
61 A. Wechsler, A. Brafman, A. Faerman, I. Bjo¨rkhem and
E. Feinstein, Science, 2003, 302, 2087.
62 J. D. Horton, J. L. Goldstein and M. S. Brown, J. Clin. Invest.,
2002, 109, 1125–1131.
63 N. Mahindroo, C. F. Huang, Y. H. Peng, C. C. Wang, C. C. Liao,
T.W. Lien, S. K. Chittimalla,W. J. Huang, C. H. Chai, E. Prakash,
C. P. Chen, T. A. Hsu, C. H. Peng, I. L. Lu, L. H. Lee, Y.W. Chang,
Paper Molecular BioSystems
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
Se
pt
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
4/
04
/2
01
5 
11
:1
4:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
96 | Mol. BioSyst., 2015, 11, 86--96 This journal is©The Royal Society of Chemistry 2015
W. C. Chen, Y. C. Chou, C. T. Chen, C. M. V. Goparaju, Y. S.
Chen, S. J. Lan, M. C. Yu, X. Chen, Y. S. Chao, S. Y. Wu and
H. P. Hsieh, J. Med. Chem., 2005, 48, 8194–8208.
64 L. G. D. Fryer, A. Parbu-Patel and D. Carling, J. Biol. Chem.,
2002, 277, 25226–25232.
65 B. M. Spiegelman, Diabetes, 1998, 47, 507–514.
66 I. Szatmari, A. Pap, R. Ruhl, J.-X. Ma, P. A. Illarionov, G. S.
Besra, E. Rajnavolgyi, B. Dezso and L. Nagy, J. Exp. Med.,
2006, 203, 2351–2362.
67 M. Pal, M. J. Tan, R.-L. Huang, Y. Y. Goh, X. L.
Wang, M. B. Y. Tang and N. S. Tan, PLoS One, 2011, 6,
e25377.
68 H. Elrod and S. Sun, PPAR Res., 2008, 704165, DOI: 10.1155/
2008/704165.
69 J. Hert, M. J. Keiser, J. J. Irwin, T. I. Oprea and B. K.
Shoichet, J. Chem. Inf. Model., 2008, 48, 755–765.
70 Y. C. Martin, J. L. Kofron and L. M. Traphagen, J. Med.
Chem., 2002, 45, 4350–4358.
Molecular BioSystems Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
Se
pt
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
4/
04
/2
01
5 
11
:1
4:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
